Board of Directors 

Board of Directors

Ken Kelley


Ken Kelley has over 35 years of entrepreneurial, venture capital, operational and technical biotechnology experience. He currently serves on the Board of Directors of Adjuvance Technologies, ID Biologics, Meissa Vaccines, Public Health Vaccines, and publicly held Halozyme Therapeutics. Previously, Mr. Kelley was co-founder, CEO and Chairman of PaxVax. Mr. Kelley was a venture capitalist at K2 BioVentures, Latterell Venture Partners and Institutional Venture Partners (IVP) and has made over 40 biotechnology and medical startup investments. Mr. Kelley was a White House Presidential Executive Fellow from 2016-2017 as well as an Advanced Leadership Initiative (ALI) Fellow at Harvard University from 2015-2016. He earned an M.B.A. from Stanford University and a B.A. in Biochemical Sciences from Harvard University.

Pete Leone


Pete Leone, MBA, joined SeromYx’s Board of Directors in late 2019. He is life sciences entrepreneur with over twenty-five years of demonstrated success in bio-pharmaceuticals and medical devices. Pete consults with various early stage biotechs in business development and strategic transactions and serves on corporate and not-for-profit Boards. Most recently, Pete led business development efforts for Bicycle Therapeutics as Chief Business Officer.

Previously, Pete was the Vice President of Strategic Business Initiatives at Arrowhead Pharmaceuticals, where he led a $3.7 billion deal with Janssen Pharmaceuticals which included $250 million in upfront cash and equity at a premium. Before that, he was founding CEO or COO at three venture backed companies, including Mersana Therapeutics, where he focused on raising capital and building the company’s platform technology and product pipeline. In his career, Pete negotiated and managed alliances in twenty-four strategic corporate agreements and nine academic technology licenses, including a $670 million collaboration with Amgen and $340 million collaboration with Teva. He has helped several companies from inception to major value creating milestones including validating deals, INDs, clinical development, FDA clearance, payer contracting, patient advocacy, and revenues.

Early in his career, Pete worked in Systems Engineering at General Electric, in marketing at Procter & Gamble, and was a Partner at Corporate Decisions, now part of Mercer. Pete holds an A.B. in engineering science with pre-med studies from Dartmouth College and an MBA from the Stanford University Graduate School of Business.

Piers Whitehead
Chief Executive Officer

Piers Whitehead has over 20 years of experience in the biopharma industry with a focus on commercial and business development functions in the fields of vaccines, immunology and public health.  Over his career to date, he has led partnering transactions that generated over $450m in cash, played a key role in an IPO, led a complex acquisition and integration, led a multi-national, multi-product commercial function, co-authored US government grants and contracts with a headline value of greater than $1bn and executed multiple in-licenses from academia, the US Government and private companies.  As Chief Business Officer of PaxVax, he led a successful process to sell a Priority Review Voucher; in-licensed the IP for the Company’s second commercial product; and designed and executed the acquisition and integration of vaccine assets from J&J/Crucell. Mr Whitehead holds a BA with honours from Oxford University.

Board Observers and Strategic Advisors

Dr. Armin Spura

Dr. Armin Spura became a Strategic Advisor and Board Observer to SeromYx in Oct 2021.  Dr. Spura is the CEO of Crown Bioscience, a leading global pre-clinical and translational contract research organization with a particular focus in oncology. Prior to Crown Bioscience Dr. Spura led the Asia Pacific and Greater China expansion strategy for CareDx, a leader in transplant diagnostics, as well as global product commercialization efforts for Wuxi NextCODE’s data analysis and AI solutions. He has also held multiple leadership positions at Life Technologies and Thermo Fisher Scientific, as General Manager for a China-based joint venture with Da’An Diagnostics, as well as GM for Professional Services for the Genomics Business. Earlier in his career, Dr. Spura helped grow two start-up companies: Ingenuity Systems (acquired by Qiagen) and ForteBio (now part of Danaher). Dr. Spura studied Biochemistry in Germany and received his PhD in Molecular Biology from Brown University.

William Robb

William Robb became a Strategic Advisor and Board Observer to SeromYx in Oct 2021 and is a partner at Madryn Asset Management, a healthcare focused alternative investment manager. Prior to joining Madryn, he was the owner of Riverpath, LLC, an investment and capital-raising advisory firm to life-sciences funds and companies. From 2010 to 2019, Mr. Robb was a Founding Partner of NovaQuest Capital Management, LLC. He was a leader in the growth of NovaQuest from its IQVIA (Quintiles) spinout to $2.75 billion in assets under management, across multiple funds and platforms (Product-based Finance and Private Equity). He was a member of the management company and investment committees of NovaQuest Pharma Opportunities Funds III, IV and V. Mr. Robb has had leadership in more than $3.0 billion of life sciences asset-based finance, equity, and structured debt investments over 20 years. From 2000 to 2010, he was a Vice President with IQVIA (Quintiles) corporate development, leading asset-based investment partnerships in the global biopharmaceutical industry. From 1997 to 2000, he was a Senior Consultant with the Wilkerson Group, managing strategic consulting projects for life sciences industry companies and private equity firms. Mr. Robb graduated with honors from Princeton University and obtained an MBA from The Kellogg Graduate School of Management at Northwestern University, where he majored in corporate finance, strategy and life sciences industry management.

Let's Talk - Contact us today to discuss your project.